An emerging immunotherapy is infusion of tumor infiltrating Lymphocytes (TIL), with objective response rates of around 50% versus 19% for ipilimumab. As an Advanced Therapeutic Medicinal Products (ATMP), TIL is highly personalized and complex therapy. | Early cost-effectiveness of tumor infiltrating lymphocytes TIL for second line treatment in advanced melanoma A model-based economic evaluation